Drugs facing NCE-1 in 2031

1. List of Vivjoa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8236962 MYCOVIA PHARMS Metalloenzyme inhibitor compounds
Apr, 2031

(8 years from now)

US9840492 MYCOVIA PHARMS Antifungal compounds and processes for making
Mar, 2036

(13 years from now)

US10414751 MYCOVIA PHARMS Antifungal compounds and processes for making
Mar, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8754227 MYCOVIA PHARMS Metalloenzyme inhibitor compounds
Apr, 2031

(8 years from now)

US11247981 MYCOVIA PHARMS Metalloenzyme inhibitor compounds
May, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 26, 2027
Generating Antibiotic Incentives Now (GAIN) Apr 26, 2032

Drugs and Companies using OTESECONAZOLE ingredient

NCE-1 date: April, 2031

Market Authorisation Date: 26 April, 2022

Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential

Dosage: CAPSULE;ORAL

More Information on Dosage

2. List of Voquezna Dual Pak drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7977488 PHATHOM 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186411 PHATHOM Pharmaceutical composition
Aug, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 3, 2027
Generating Antibiotic Incentives Now (GAIN) May 3, 2032

Drugs and Companies using AMOXICILLIN; VONOPRAZAN FUMARATE ingredient

NCE-1 date: May, 2031

Market Authorisation Date: 03 May, 2022

Treatment: NA

Dosage: CAPSULE, TABLET;ORAL

More Information on Dosage

3. List of Voquezna Triple Pak drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7977488 PHATHOM 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186411 PHATHOM Pharmaceutical composition
Aug, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 3, 2027
Generating Antibiotic Incentives Now (GAIN) May 3, 2032

Drugs and Companies using AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE ingredient

NCE-1 date: May, 2031

Market Authorisation Date: 03 May, 2022

Treatment: NA

Dosage: CAPSULE, TABLET, TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in